POLARYX THERAPEUTICS
Polaryx Therapeutics is a biopharmaceutical company that provides molecule therapeutics development and clinical trial services.
POLARYX THERAPEUTICS
Industry:
Biopharma Biotechnology Medical
Founded:
2014-01-01
Address:
Paramus, New Jersey, United States
Country:
United States
Website Url:
http://www.polaryx.com
Total Employee:
1+
Status:
Active
Contact:
+1 201-940-7236
Email Addresses:
[email protected]
Technology used in webpage:
Euro Mobile Non Scaleable Content IPv6 Cloudflare Hosting Common Name Invalid
Similar Organizations
Aptiv Solutions
Aptiv is a biopharmaceutical and medical device company that offers a variety of clinical trial services.
Cetek Corporation
Cetek Corporation is a biopharmaceutical company that engages in the discovery and development of novel cancer therapeutics.
Emerson Resources
Emerson Resources is a pharmaceuticals company that offers drug product development and analytical services.
Kojin Therapeutics
Kojin is a biopharmaceutical company that develops new targeted therapeutics based on cell state and ferroptosis biology.
NanoViricides
NanoViricides is a nano-biopharmaceutical company that develops therapeutics for patients suffering from life-threatening viral infections.
Rumpus Therapeutics
Rumpus Therapeutics is a biopharmaceutical company that offers clinical development, portfolio management & research on pediatric diseases.
Current Employees Featured
Official Site Inspections
http://www.polaryx.com Semrush global rank: 4.79 M Semrush visits lastest month: 1.86 K
- Host name: 183178043146.ctinets.com
- IP address: 183.178.43.146
- Location: Central Hong Kong
- Latitude: 22.2909
- Longitude: 114.15
- Timezone: Asia/Hong_Kong
More informations about "Polaryx Therapeutics"
Polaryx Therapeutics | Combating Lysosomal Storage Disorders
Polaryx Therapeutics, Inc. is a late-stage clinical biotech company focused on developing patient-friendly small molecule treatments for lysosomal storage disorders (LSDs). Founded in 2014, …See details»
Our Leadership - polaryx
Alex Yang, J.D., LL.M. is the CEO/owner of Mstone Partners, which serves as the major shareholder of Polaryx. Since 2016, Alex has served in senior management and chair of board …See details»
Polaryx Therapeutics - Crunchbase Company Profile & Funding
Organization. Polaryx Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Polaryx Therapeutics is a biopharmaceutical …See details»
What We Do - polaryx
With a patient-first approach in our R&D process, Polaryx is committed to developing non-invasive therapeutic alternatives to treat lysosomal storage disorders. Our orally-available small …See details»
Polaryx®
PARAMUS, N.J., Aug. 30, 2021 /PRNewswire/ -- Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced …See details»
Polaryx Therapeutics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Polaryx Therapeutics Inc of Paramus, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Polaryx Therapeutics Company Profile 2024: Valuation, Funding ...
Polaryx Therapeutics General Information Description. Developer of small molecule therapeutics designed to provide treatment for lysosomal storage disorders. The company's therapeutics …See details»
What We Do - Polaryx®
Developing patient-friendly, orally-available therapeutics for lysosomal storage disorders. Enhancing cellular clearance pathways to eliminate waste.See details»
Polaryx Therapeutics - Contacts, Employees, Board Members
Organization. Polaryx Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Polaryx …See details»
Polaryx Therapeutics - Overview, News & Similar companies
May 4, 2022 Polaryx Therapeutics, Inc. is a multi-asset, late-stage clinical biopharmaceutical company developing patient-friendly small molecule therapeutics for rare, inherited lysosomal …See details»
Our Science - polaryx
Polaryx’s drug candidates are intended to treat lysosomal storage disorders, where cellular toxic wastes are responsible for the disease pathogenesis. Batten Disease . Neuronal Ceroid …See details»
Polaryx Therapeutics Company Profile -Sales, Contacts, …
Polaryx Therapeutics is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately 8 years. The Most …See details»
Polaryx Therapeutics Appoints Ronald Moss as CMO and G.
Jul 10, 2024 I look forward to working with the team to accelerate Polaryx’s pipeline development and important work in the clinic,” said Dr. Moss. G. Michael Landis Immediately …See details»
Polaryx Therapeutics Receives FDA Orphan Drug Designation
Sep 2, 2021 Polaryx Therapeutics, Inc. is developing drug candidates for lysosomal storage disorders, for which there are currently no safe and patient-friendly treatment options …See details»
Polaryx Therapeutics Receives FDA Orphan Drug Designation for …
Sep 2, 2021 Polaryx Therapeutics, Inc. Polaryx Therapeutics, Inc. is developing drug candidates for lysosomal storage disorders, for which there are currently no safe and patient-friendly …See details»
Clinical Trials - polaryx
Polaryx has explored relevant drug candidates and identified PLX-200 to treat CLN3 disease. More information on the trial can be found at Clinicaltrials.gov NCT04637282. If you need …See details»
Polaryx Therapeutics Receives IND Approval From the FDA to …
Apr 8, 2020 Polaryx Therapeutics, Inc is dedicated to developing drug candidates for lysosomal storage disorders, for which there is currently no safe and patient-friendly treatment option …See details»
Polaryx Therapeutics Announces FDA Grants Orphan Drug …
Aug 30, 2021 Polaryx Therapeutics, Inc. Lysosomal storage disorders are a group of rare inherited genetic disorders caused by the dysfunction of lysosomal enzymes and/or molecules …See details»
Our Pipeline - polaryx
PLX-400 is an early-stage gene therapy. Polaryx is in the process of completing pre-clinical work and plans to move quickly towards an IND filing with the FDA. PLX-400 works by …See details»
Patient-friendly treatments for neuronal ceroid lipofuscinoses
Been used is significant. Polaryx aims to rapidly develop safe and convenient drugs. The speed and existing safety repurposing data, as well as the con - venience of oral small molecules, …See details»